🇺🇸 FDA
Patent

US 11872200

GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

granted A61KA61K31/197A61K31/4465

Quick answer

US patent 11872200 (GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes) held by The Regents of the University of California expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/197, A61K31/4465, A61K38/2013, A61K39/0008